Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners

doi:10.12114/j.issn.1007-9572.2021.00.133

Abstract

Abstract: The recent updates of guidelines for the management of gout have gradually promoted the standardization of gout diagnosis and treatment. What's more，the newly released 2020 American College of Rheumatology Guideline for the Management of Gout has made some vague concepts to be clear. As general practitioners play a vital role in the management of gout，a common and frequently-occurring disease，we interpreted the 2020 American College of Rheumatology Guideline for the Management of Gout from their perspective，and compared it to the latest Chinese guideline for the management of gout，offering proposal ideas to help general practitioners with the diagnosis and treatment of gout.

Key words: Gout, Hyperuricemia, Guideline, General practitioner

摘要：

近年来，国内外痛风治疗指南不断更新，使痛风诊治逐渐变得规范。随着《2020年美国风湿病学会痛风治疗指南》的公布，一些模糊的概念越来越清晰。痛风作为一种常见病、多发病，全科医生在痛风的治疗中起着至关重要的作用。本文将从全科医生的角度论述《2020年美国风湿病学会痛风治疗指南》，并与我国最新版痛风治疗指南进行对比，为全科医生诊治痛风提供参考建议。

关键词: 痛风, 高尿酸血症, 指南, 全科医生

LIU Min,MENG Juan. Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners　[J]. Chinese General Practice, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.
刘敏,孟娟. 基于全科医生视角的《2020年美国风湿病学会痛风治疗指南》解读[J]. 中国全科医学, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.

References

［1］中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南（2019）［J］. 中华内分泌代谢杂志，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
Chinese Society of Endocrinology. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China（2019）［J］. Chinese Journal of Endocrinology and Metabolism，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
［2］FITZGERALD J D，DALBETH N，MIKULS T，et al. 2020 American College of Rheumatology Guideline for the Management of Gout［J］. Arthritis Care Res（Hoboken），2020，72（6）：744-760. DOI：10.1002/acr.24180.
［3］CAMPION E W，GLYNN R J，DELABRY L O. Asymptomatic hyperuricemia risks and consequences in the normative aging study［J］. Am J Med，1987，82（3）：421-426.
［4］KHANNA D，KHANNA P P，FITZGERALD J D，et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia［J］. Arthritis Care Res（Hoboken），2012，64（10）：1431-1446.
［5］中华医学会. 痛风及高尿酸血症基层诊疗指南（2019年）［J］. 中华全科医师杂志，2020，19（4）：293-303. DOI：10.3760/cma.j.cn114798-20200328-00382.
［6］邹和建. 强基层，提升痛风诊疗水平［J］. 中华全科医师杂志，2020，19（4）：288-289. DOI：10.3760/cma.j.cn114798-20200330-00389.
［7］WHITE W B，SAAG K G，BECKER M A，et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］. N Engl J Med，2018，378（13）：1200-1210. DOI：10.1056/NEJMoa1710895.
［8］YAMMANAKA H，TAMAKI S，IDE Y，et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy：results from FORTUNE-1，a prospective，multicentre randomised study［J］. Ann Rheum Dis，2018，77（2）：270-276. DOI：10.1136/annrheumdis-2017-211574.
［9］ MICHELLE H，ALISON C，STEWART C，et al. The British Society for Rheumatology Guideline for the Management of Gout［J］. Rheumatology，2017，56（7）：1056-1059.
［10］HILL E M，SKY K，SIT M，et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial［J］. Clin Rheumatol，2015，21（3）：120-125. DOI：10.1097/RHU.0000000000000235.
［11］TAYLOR T H，MECCHELLA J N，LARSON R J，et al. Initiation of allopurinol at first medical contact for acute attacks of gout：a randomized clinical trial［J］. Am J Med，2012，125（11）：1126-1134. DOI：10.1016/j.amjmed.2012.05.025.
［12］DOHERTY M，JENKINS W，RICHARDSON H，et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout：a randomised controlled trial ［J］. Lancet，2018，392（10156）：1403-1412. DOI：10.1016/S0140-6736(18)32158-5.
［13］CHEN C H，CHEN C B，CHANG C J，et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians：a population-based cohort study and meta-analysis［J］. Clinical Pharmacology and Therapeutics，2019，106（2）：391-401. DOI：10.1002/CPT.1377.
［14］MOHAMED O，CARL S，LI J，et al. Dipstick spot urine pH does not accurately represent 24 hour urine pH measured by an electrode［J］. Int Braz J Urol，2016，42（3）：546-549. DOI：10.1590/S1677-5538.IBJU.2015.0071.
［15］YU K H，CHEN D Y，CHEN J H，et al. Management of Gout and Hyperuricemia：Multidisciplinary Consensus in Taiwan［J］. International Journal of Rheumatic Diseases，2018，21（4）：772-787. DOI：10.1111/1756-185x.13266.
［16］PEREZ-RUIZ F，CALABOZO M，PIJOAN J I，et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout［J］. Arthritis Rheum，2002，47（4）：356-360. DOI：10.1002/art.10511.
［17］史晓飞，徐东，帅宗文，等. 痛风相关知识问答（二）：痛风急性发作期及预防发作治疗篇［J］. 中华内科杂志，2018，57（10）：759-760. DOI：10.3760/cma.j.issn.0578-1426.2018.10.013.
［18］CHOI H K，ATKINSON K，KARLSON E W，et al. Obesity，weight change，hypertension，diuretic use，and risk of gout in men［J］. Arch Intern Med，2005，165（7）：742-748. DOI：10.1001/archinte.165.7.742.
［19］WALDMAN B，ANSQUER J C，SULLIVAN D R，et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes：a post-hoc analysis of the randomised，controlled FIELD study［J］. Lancet Diabetes Endocrinol，2018，6（4）：310-318. DOI：10.1016/S2213-8587(18)30029-9.

[1]	WEI Baian, YU Yan, QIU Xingying, GUO Xinfeng, YANG Lihong. The Delphi Critical Appraisal Tool: Interpretation and Practical Applications [J]. Chinese General Practice, 2026, 29(32): 4700-4709.
[2]	China Sport Science Society. Guidelines for Exercise Prescription of Dyslipidemia [J]. Chinese General Practice, 2026, 29(32): 4673-4689.
[3]	JIANG Huajie, ZHUO Lin, LI Xinyue, JIN Rui, MA Yue, CUI Jingqiu, WANG Xiuying. Related Factors and Preventive Measures of Hyperuricemia in Elderly Men [J]. Chinese General Practice, 2026, 29(27): 3915-3923.
[4]	QU Furong, JIN Jiaqi, XUE Guijun, LYU Qingguo, LI Zhipeng, LI Jing, LI Sheyu. Interpretation of the BMJ Living Clinical Practice Guideline on Pharmacological Management of Type 2 Diabetes Based on Cardiovascular-renal Event Prevention and Weight Management [J]. Chinese General Practice, 2026, 29(27): 3873-3878.
[5]	YANG Rui, LIAO Xiaoyang, HUANG Chuanying, YANG Ziyu, SHEN Can, JIA Yu, LIU Lidi, YANG Rong. Interpretation of the 2024 British and Irish Hypertension Society Position Statement: Investigation and Management of Hypertension in Young People [J]. Chinese General Practice, 2026, 29(26): 3726-3732.
[6]	LI Haijin, ZHU Chenli, LI Hui, FENG Zhengwen, QIAO Yuchen, DU Juan. Quality Evaluation and Content Analysis of Guidelines Related to Post-diagnosis Management of Dementia [J]. Chinese General Practice, 2026, 29(25): 3569-3576.
[7]	XIE Wan, TU Xulian, WU Liping, LIU Xia, LI Xiaoyan, LENG Mingyue, YANG Xueqing, LI Li. A Systematic Review of Guidelines and Expert Consensus Related to Pain Management in Endometriosis [J]. Chinese General Practice, 2026, 29(23): 3351-3358.
[8]	XU Kun, CHENG Jingwei, WANG Congshuai, WANG Yinhao, HU Junpeng, LI Wanyue, LIU Yangqing, XI Yan. The Role of Exercise in the Management of Metabolic-associated Fatty Liver Disease: Interpretation of the International Expert Consensus of ACSM and ESSA [J]. Chinese General Practice, 2026, 29(23): 3253-3260.
[9]	LIN Zina, CUI Liangyu, JING Tianyue, LIU Dasheng, ZHAO Xueyao, HAN Xuejie, WANG Liying. Analysis of Methods for Raising Clinical Questions and Influencing Factors in Domestic and International Clinical Practice Guideline Development Manuals [J]. Chinese General Practice, 2026, 29(23): 3342-3350.
[10]	Expert Group on Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China, Professional Committee on Obesity Control in Women and Children, China Maternal and Child Health Research Association. Guidelines for the Assessment, Treatment, and Prevention of Childhood Obesity in China (Second Edition) [J]. Chinese General Practice, 2026, 29(23): 3233-3252.
[11]	QU Furong, ZHAO Lijun, ZENG Xiaoxi, LI Jing, LI Sheyu. Interpretation of BMJ Clinical Practice Guideline: SGLT-2 Inhibitors for Adults with Chronic Kidney Disease [J]. Chinese General Practice, 2026, 29(22): 3079-3085.
[12]	LI Ge, ZHOU Yingsheng, TIAN Xiangyang, GAO Ying. Interpretation of the ACLM Clinical Practice Guideline: Lifestyle Interventions for the Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults [J]. Chinese General Practice, 2026, 29(22): 3086-3093.
[13]	SHI Jinjie, WEI Guangcheng, ZHANG Xinwen, LUO Ye, ZHU Ke, YANG Yue, LI Xiaoxu, YANG Hongyu, MA Rui, ZHANG Jieyu, DU Jieyang, YA Yulong, PENG Jiucheng, CAO Wei. An Evidence-based Evaluation of the Efficacy of Simiao Pill in the Treatment of Gouty Arthritis Based on GRADE and an Integrated Evidence Chain [J]. Chinese General Practice, 2026, 29(21): 3046-3055.
[14]	CHEN Dian, LONG Huanyu, CHU Lanhe, JIANG Yixia, GUO Wanjin, NIU Yang, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2026 Report [J]. Chinese General Practice, 2026, 29(21): 2913-2932.
[15]	CHEN Xiangyang, HUANG Hongmei, LI Sheyu. Prevention and Management of Adult Obesity: Progress and Trends from Six Keywords in 2025 [J]. Chinese General Practice, 2026, 29(20): 2753-2758.